Davis Jason 4

What Happened Jason Davis, Chief Financial Officer of FibroBiologics, was granted an option to purchase 61,607 shares of the company's common stock. The Form 4 reports the grant as a derivative acquisition at $0.00 on May 4, 2026 — this reflects an option award, not a purchase of shares or an exercise that generated cash proceeds.

Key Details

• Transaction date and filing: May 4, 2026 (Form 4 filed same day).
• Reported price: $0.00 (derivative award — option grant as reported on the Form 4).
• Shares involved: option to acquire 61,607 shares.
• Vesting: 1/4 of the option vests on the one-year anniversary of the grant; the remaining shares vest in 36 equal monthly installments thereafter (standard four-year schedule tied to continued service).
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan, tax-withholding, or late-filing notes were disclosed in the Form 4.

Context This filing documents an option grant (an award of the right to buy future shares if/when vested and exercised), not an immediate purchase or sale of stock. Because vesting is time‑based, the award only converts into exercisable rights over the next several years subject to continued service. Such grants are common part of executive compensation and do not by themselves indicate immediate buying or selling in the open market.